EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Preventive effects of dexamethasone oral solution on radiation-induced mucositis in patients with head and neck cancer: a randomized, triple-blind, parallel-group trial

Niloofar Ahmadlo, Nooshin Dindar, Mohammad Mohammadianpanah, Shapour Omidvari, Ahmad Mosalaei, Mansour Ansari, Hamid Nasrolahi, Behnam Kadkhodaei, Mahdi Shariat, Nezhat Khanjani, James S Welsh, Seyed Alireza Javadinia

Supportive Care in Cancer · 2026-04 · 34 (4)

DOI: 10.1007/s00520-026-10603-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 02.04.2026. Verfasst von Niloofar Ahmadlo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Dexamethasone, Stomatitis, Radiation Injuries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Radiation-induced oral mucositis is a frequent and debilitating complication of curative radiotherapy for head and neck cancer. This randomized, triple-blind, placebo-controlled, parallel-group trial evaluated whether a topical dexamethasone oral solution (0.5 mg/10 mL) used as a prophylactic mouthwash reduces the incidence and severity of radiation-induced oral mucositis. METHODS: Fifty-four patients with non-metastatic head and neck squamous cell carcinoma scheduled to receive ≥ 60 Gy radiotherapy were randomized 1:1 to dexamethasone mouthwash or placebo and instructed to gargle 10 mL four times daily during radiotherapy. The primary endpoint was the incidence and maximum severity of oral mucositis occurring during radiotherapy, defined as the highest grade recorded using the WHO Oral Toxicity Scale and NCI-CTCAE criteria v. 5. Secondary endpoints included patient-reported pain (VAS), dysphagia, treatment discontinuation, and mucositis status at 2 months. Fifty patients completed the study (25 per arm); four patients discontinued (reasons reported in Results). RESULTS: The dexamethasone group had significantly lower mucositis severity at all time points by WHO and CTCAE scales (all p < 0.01), a delayed peak severity (week 5 vs week 3), lower pain scores from weeks 4-7 (median VAS 0-3 versus 4-6; p < 0.01), and lower dysphagia at 2 months (32% vs 72%; p = 0.01). No grade 4 mucositis occurred in the dexamethasone arm; two grade 4 events occurred in placebo. There were no statistically significant differences in treatment discontinuation. Topical dexamethasone was well tolerated; no signal of treatment-related systemic steroid toxicity or increased oral infections was observed. CONCLUSION: In this phase II study, prophylactic topical dexamethasone mouthwash reduced the severity and delayed the onset of radiation-induced oral mucositis and improved patient-reported pain. These findings are promising but require confirmation in larger multicenter trials with longer follow-up and formal patient-reported outcomes (e.g., EORTC QLQ-H&N35, OMAS) and comparison with guideline-recommended strategies such as photobiomodulation. TRIAL REGISTRATION NUMBER: Iranian Registry of Clinical Trials; trial registration number: IRCT20240525061893N1; date of registration: 21 July 2024.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsDexamethasoneStomatitisRadiation InjuriesHumansFemaleMaleMiddle AgedAgedMouthwashesDouble-Blind MethodAdultSeverity of Illness IndexCarcinoma, Squamous CellAdministration, OralAnti-Inflammatory AgentsSquamous Cell Carcinoma of Head and Neck

Stichwörter der Autor:innen

DexamethasoneHead and neck cancerOral solutionRadiation-induced mucositisRandomized controlled trialSupportive care

Substanzen

DexamethasoneMouthwashesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Radiation Oncology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. nooshindindar@ymail.com.
  • Department of Radiation Oncology, Loyola University Chicago Stritch School of Medicine, Edward Hines Jr., VA Hospital, Maywood, IL, USA.
  • Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran. Javadinia.alireza@gmail.com.

Förderung

  • Shiraz University of Medical Sciences

Zitieren

APA

Ahmadlo, N., Dindar, N., Mohammadianpanah, M., Omidvari, S., Mosalaei, A., Ansari, M., Nasrolahi, H., Kadkhodaei, B., Shariat, M., Khanjani, N., Welsh, J. S., & Javadinia, S. A. (2026). Preventive effects of dexamethasone oral solution on radiation-induced mucositis in patients with head and neck cancer: a randomized, triple-blind, parallel-group trial. Supportive Care in Cancer, 34(4). https://doi.org/10.1007/s00520-026-10603-3

Vancouver

Ahmadlo N, Dindar N, Mohammadianpanah M, Omidvari S, Mosalaei A, Ansari M, et al. Preventive effects of dexamethasone oral solution on radiation-induced mucositis in patients with head and neck cancer: a randomized, triple-blind, parallel-group trial. Supportive Care in Cancer. 2026;34(4). doi:10.1007/s00520-026-10603-3

BibTeX
@article{Ahmadlo2026,
  author = {Ahmadlo, Niloofar and Dindar, Nooshin and Mohammadianpanah, Mohammad and Omidvari, Shapour and Mosalaei, Ahmad and Ansari, Mansour and Nasrolahi, Hamid and Kadkhodaei, Behnam and Shariat, Mahdi and Khanjani, Nezhat and Welsh, James S and Javadinia, Seyed Alireza},
  title = {Preventive effects of dexamethasone oral solution on radiation-induced mucositis in patients with head and neck cancer: a randomized, triple-blind, parallel-group trial},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {4},
  doi = {10.1007/s00520-026-10603-3}
}
Kostenlos starten →